This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
9 Challenges During Cell and Gene Therapy Development in Europe, and How to Tackle Them
Published on: Mar 9th, 2017
Developing gene and cell-based medicinal products (referred to as “Advanced therapy medicinal products” in Europe) still represents huge challenges. At the same time, these breakthrough therapies bring hope for filling unmet medical needs and curing life-threatening diseases. Knowledge of the European regulatory framework for ATMPs and their main development hurdles is crucial, especially for academics & sponsors based outside the European Union.
Key learning objectives:
- EU regulatory framework for ATMPs
- Main CMC (Chemistry Manufacturing and Control), NC (Non-Clinical) and C (Clinical) challenges during ATMP development
- Introduction to an integrative approach for ATMP development
G. Narayanan, Vice President, Disruptive Biologics and E. Sabbah-Petrover, PhD., Associate Director at VCLS, will share their experience of ATMP development and their assessment at national and European levels. M. Deneux, PhD., Senior Director, Regulatory Science, Drugs & Biologics at VCLS will moderate the session.
SAMPLE OF THE WEBINAR
9 Challenges During Cell and Gene Therapy Development in Europe, and How to Tackle Them
Access the full webinar replay now
Fill in the form to download the content